Fulgent Genetics, Inc. (FLGT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Fulgent Genetics operates two primary segments: Laboratory Services (precision diagnostics, anatomic pathology, and BioPharma services) and Therapeutic Development (drug candidates for cancer treatment). During the quarter, the Company completed the acquisition of ANP Technologies, Inc. (ANP) on July 9, 2025, to secure ownership of patents and technologies utilized in its therapeutic development pipeline.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $84,069 | $71,743 | $239,335 | $207,256 |
| Gross Profit | $35,512 | $26,771 | $98,293 | $75,366 |
| Gross Margin | 42.2% | 37.3% | 41.1% | 36.4% |
| Operating Loss | $(15,350) | $(17,079) | $(54,858) | $(57,783) |
| Net Loss (Attributable to Fulgent) | $(6,608) | $(14,648) | $(37,095) | $(36,820) |
| Diluted EPS | $(0.21) | $(0.48) | $(1.21) | $(1.22) |
| Cash & Cash Equivalents | $117,641 | $55,144 | As of Sept 30, 2025 | |
| Total Marketable Securities | $669,940 | $773,313 | As of Sept 30, 2025 | |
| Total Debt (Notes Payable) | $2,434 | $2,905 | As of Sept 30, 2025 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17% quarter-over-quarter (QoQ) and 16% year-to-date (YTD). Growth was driven by Precision Diagnostics (+16% QoQ), Anatomic Pathology (+7% QoQ), and BioPharma Services (+83% QoQ). COVID-19 revenue was negligible in 2025 compared to $2.1M in the prior YTD period.
- Margin Expansion: Gross margin improved to 42% in Q3 2025 from 37% in Q3 2024, attributed to streamlined operations and efficiency gains from scaling lab operations.
- Operating Expenses: Total operating expenses rose 16% QoQ. Notable increases included Selling and Marketing (+28%) and General and Administrative (+11%). The G&A increase included a $9.0M provision for credit losses and $2.2M in legal fees (partially offset by a reversal of prior year accruals).
- Impairment Loss: The Company recognized a non-cash impairment loss of approximately $9.9M related to an investment in Helio Genomics, Inc. This charge was recorded in "Other Expenses" for the nine months ended September 30, 2025. No impairment loss was recorded in Q3 2024.
- Acquisition: The acquisition of ANP Technologies added $3.0M in goodwill and $3.9M in in-process research and development (IPR&D) assets. ANP contributed $0.1M in revenue since the acquisition date.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to continue increasing as clinical trials for drug candidates FID-007 and FID-022 progress. The Company anticipates existing cash and marketable securities will be sufficient to meet requirements for at least the next 12 months.
- Tax Credits: The Company purchased $33.8M of Investment Tax Credits (ITCs) in the first nine months of 2025 and an additional $72.4M in October 2025 (subsequent event). Refunds totaling approximately $106.7M are expected from the IRS but may be delayed due to the U.S. government shutdown.
- Legal & Regulatory Risks: The Company is subject to ongoing investigations by the U.S. Department of Justice (DOJ) regarding the False Claims Act and an audit by the Health Resources and Services Administration (HRSA) regarding COVID-19 reimbursements. The Company cannot currently estimate the potential financial impact of these matters.
- Customer Concentration: One customer accounted for 23% of total revenue in both Q3 2025 and Q3 2024. The Company is actively working to diversify its customer base to mitigate this risk.
Key Investor Verification Points
- Government Shutdown Impact: Verify the status of expected tax credit refunds (~$106.7M) and potential delays in FDA review timelines due to the government shutdown.
- Legal Contingencies: Monitor developments in the DOJ Civil Investigative Demand (CID) and HRSA audit, as outcomes could materially affect financial condition.
- Customer Concentration: Assess the stability of the single customer representing 23% of revenue and the effectiveness of diversification efforts.
- Therapeutic Pipeline Progress: Track clinical trial milestones for FID-007 and FID-022, which are driving increased R&D spend.
- Stock Repurchases: Note that $139.6M remains available under the $250M repurchase program, with $10.9M utilized YTD 2025.